Fragility in cardiovascular randomized controlled trials with primary continuous outcomes (2018–2022) from multi-perspectives assessment: a cross-sectional survey

Xiaoqin Zhou Weiqiang Ruan Guiying Zhang Huizhen Liu Ting Wang Jing Li Liang Du Jin Huang a Department of Cardiovascular Surgery,West China Hospital,Sichuan University,Chengdu,P.R. Chinab Research Center of Clinical Epidemiology and Evidence-Based Medicine,West China Hospital,Sichuan University,Chengdu,P.R. Chinac Center of Biostatistics,Design,Measurement and Evaluation (CBDME),Department of Clinical Research Management,West China Hospital,Sichuan University,Chengdu,P.R. Chinad Department of Urology,Innovation Institute for Integration of Medicine and Engineering,West China Hospital,Sichuan University,Chengdu,P.R. China
DOI: https://doi.org/10.1080/07853890.2024.2427909
IF: 5.348
2024-12-04
Annals of Medicine
Abstract:Objective This study aims to assess the robustness of cardiovascular disease randomized controlled trials (RCTs) with primary continuous outcomes from a clinical perspective, utilizing the concepts of continuous fragility index (CFI), reverse continuous fragility index (RCFI) and their corresponding quotients (CFQ, RCFQ).
medicine, general & internal
What problem does this paper attempt to address?